ClinicalTrials.gg
CompletedNCT06743594Updated Oct 6, 2026

Measurement of Antioxidant Activity and Oxidative Stress in Patients Undergoing Ophthalmic Surgery.

An observational study in Cataract and Myopia, sponsored by Chang Gung Memorial Hospital. Completed at 2 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Chang Gung Memorial Hospital · Observational

How we know

Updated Oct 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Cataract with a site in Taiwan — 2 open to participants now, 2 under way, none of them phase 3. Cataract · Taiwan.

Started
2025
with 2 others
Observational
6 of 15
none open now
Registered
12th of 15
by date
Lead sponsor
4 of 15
Chang Gung Memorial Hospital

Among the 15 studies in Cataract with a site in Taiwan, this one is one of 3 that started in 2025, is one of 6 observational ones, and was the 12th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

2 of the 15 studies in Cataract with a site in Taiwan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Cataract with a site in Taiwan, or all of them as a file.
02

Study summary

This trial hypothesized that novel laser refractive surgery techniques (LASIK, KLEx) or laser-assisted cataract surgery (FLACAS) could suppress postoperative inflammation and improve recovery in patients by reducing oxidative stress generated by the surgical procedure. It is also intended to verify whether the new laser technology is necessary for clinical use in groups with low antioxidant activity through the detection of antioxidant activity in the eyes of patients.

Read the detailed description

Simultaneously measure total reactive oxygen species (ROS), antioxidant capacity (TAC) and ascorbic acid (AA) in aqueous humor (cataract surgery only) or tears. All patients underwent the same examination at our institution, including uncorrected visual acuity (UCVA), intraocular pressure (IOP), as well as central corneal thickness (CCT) with pneumatic tonometer, apparent refraction with autorefractor, and corneal curvature with keratometer. The axial length (AXL), anterior chamber depth (ACD) and lens thickness (LT) were measured by optical biometer.

03

Conditions studied

  • Cataract
  • Myopia

Keywords

  • antioxidants
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study included patients with the following conditions: (1) at least 20 years old, (2) expected to undergo corneal refractive surgery or cataract surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 20 years old
  • corneal refractive surgery or cataract surgery patients

Exclusion criteria

Exclusion Criteria:

  • patients with eye infections
  • presence of severe retinal disease
  • presence of severe eye injury or severe ptosis
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • LASIK

    Femtosecond-LASIK in myopia

  • KLEx

    Kerato-lenticule Extraction in myopia

  • Traditional Cataract Surgery

    Cataract Surgery with Phacoemulsification

  • Laser-Assisted Cataract Surgery

    Cataract Surgery with LenSx Femtosecond Laser

06

What researchers measure

Primary outcomes

  1. TAC in tears at 1 week

    Change of Total Antioxidant Capacity (TAC) from Baseline to 1 week after surgery.

    Time frame: Before the operation and 1 week after surgery.

  2. TAC in tears at 1 month

    Change of Total Antioxidant Capacity (TAC) from Baseline to 1 month after surgery.

    Time frame: Before the operation and 1 month after surgery.

  3. TAC in tears at 2 months

    Change of Total Antioxidant Capacity (TAC) from Baseline to 2 months after surgery.

    Time frame: Before the operation and 2 months after surgery.

  4. TAC in tears at 3 months

    Change of Total Antioxidant Capacity (TAC) from Baseline to 3 months after surgery.

    Time frame: Before the operation and 3 months after surgery.

  5. AA in tears at 1 week

    Change of Ascorbic Acid (AA) from Baseline to 1 week after surgery.

    Time frame: Before the operation and 1 week after surgery.

  6. AA in tears at 1 month

    Change of Ascorbic Acid (AA) from Baseline to 1 month after surgery.

    Time frame: Before the operation and 1 month after surgery.

  7. AA in tears at 2 months

    Change of Ascorbic Acid (AA) from Baseline to 2 months after surgery.

    Time frame: Before the operation and 2 months after surgery.

  8. AA in tears at 3 months

    Change of Ascorbic Acid (AA) from Baseline to 3 months after surgery.

    Time frame: Before the operation and 3 months after surgery.

  9. ROS in tears at 1 week

    Change of Reactive Oxygen Species (ROS) from Baseline to 1 week after surgery.

    Time frame: Before the operation and 1 week after surgery.

  10. ROS in tears at 1 month

    Change of Reactive Oxygen Species (ROS) from Baseline to 1 month after surgery.

    Time frame: Before the operation and 1 month after surgery.

  11. ROS in tears at 2 months

    Change of Reactive Oxygen Species (ROS) from Baseline to 2 moths after surgery.

    Time frame: Before the operation and 2 months after surgery.

  12. ROS in tears at 3 months

    Change of Reactive Oxygen Species (ROS) from Baseline to 3 months after surgery.

    Time frame: Before the operation and 3 months after surgery.

  13. TAC in aqueous humor at the next day

    Change of Total Antioxidant Capacity (TAC) in aqueous humor from Baseline to one day after surgery

    Time frame: Before the operation and one day after surgery.

  14. AA in aqueous humor at the next day

    Change of Ascorbic Acid (AA) in aqueous humor from Baseline to one day after surgery

    Time frame: Before the operation and one day after surgery.

  15. ROS in aqueous humor at the next day

    Change of Reactive Oxygen Species (ROS) in aqueous humor from Baseline to one day after surgery

    Time frame: Before the operation and one day after surgery.

Secondary outcomes

  1. BCVA

    Examination of best corrected visual acuity (BCVA)

    Time frame: Before surgery

  2. UCVA at 1 week

    Examination of uncorrected visual acuity (UCVA)

    Time frame: 1 week after surgery

  3. UCVA at 1 month

    Examination of uncorrected visual acuity (UCVA)

    Time frame: 1 month after surgery

  4. UCVA at 2 months

    Examination of uncorrected visual acuity (UCVA)

    Time frame: 2 months after surgery

  5. UCVA at 3 months

    Examination of uncorrected visual acuity (UCVA)

    Time frame: 3 months after surgery

07

Study locations

2 sites
  • Taipei Nobel Eye Clinic
    Taipei, 100, Taiwan
  • Chang Gung Memorial Hospital
    Taoyuan, 333, Taiwan
08

References and documents

Publications

  • Umapathy A, Donaldson P, Lim J. Antioxidant delivery pathways in the anterior eye. Biomed Res Int. 2013;2013:207250. doi: 10.1155/2013/207250. Epub 2013 Sep 26. PubMed 24187660 ↗
  • Merida S, Villar VM, Navea A, Desco C, Sancho-Tello M, Peris C, Bosch-Morell F. Imbalance Between Oxidative Stress and Growth Factors in Human High Myopia. Front Physiol. 2020 May 14;11:463. doi: 10.3389/fphys.2020.00463. eCollection 2020. PubMed 32477165 ↗
  • Tsao YT, Wu WC, Chen KJ, Liu CF, Hsueh YJ, Cheng CM, Chen HC. An Assessment of Cataract Severity Based on Antioxidant Status and Ascorbic Acid Levels in Aqueous Humor. Antioxidants (Basel). 2022 Feb 16;11(2):397. doi: 10.3390/antiox11020397. PubMed 35204279 ↗
  • Kato K, Miyake K, Hirano K, Kondo M. Management of Postoperative Inflammation and Dry Eye After Cataract Surgery. Cornea. 2019 Nov;38 Suppl 1:S25-S33. doi: 10.1097/ICO.0000000000002125. PubMed 31498249 ↗
  • Hsueh YJ, Meir YJ, Lai JY, Huang CC, Lu TT, Ma DH, Cheng CM, Wu WC, Chen HC. Ascorbic acid ameliorates corneal endothelial dysfunction and enhances cell proliferation via the noncanonical GLUT1-ERK axis. Biomed Pharmacother. 2021 Dec;144:112306. doi: 10.1016/j.biopha.2021.112306. Epub 2021 Oct 15. PubMed 34656060 ↗
  • Dong Z, Zhou X, Wu J, Zhang Z, Li T, Zhou Z, Zhang S, Li G. Small incision lenticule extraction (SMILE) and femtosecond laser LASIK: comparison of corneal wound healing and inflammation. Br J Ophthalmol. 2014 Feb;98(2):263-9. doi: 10.1136/bjophthalmol-2013-303415. Epub 2013 Nov 13. PubMed 24227802 ↗
  • Seen S, Tong L. Dry eye disease and oxidative stress. Acta Ophthalmol. 2018 Jun;96(4):e412-e420. doi: 10.1111/aos.13526. Epub 2017 Aug 21. PubMed 28834388 ↗
  • Vallabh NA, Romano V, Willoughby CE. Mitochondrial dysfunction and oxidative stress in corneal disease. Mitochondrion. 2017 Sep;36:103-113. doi: 10.1016/j.mito.2017.05.009. Epub 2017 May 23. PubMed 28549842 ↗
  • Wong AHY, Cheung RKY, Kua WN, Shih KC, Chan TCY, Wan KH. Dry Eyes After SMILE. Asia Pac J Ophthalmol (Phila). 2019 Sep-Oct;8(5):397-405. doi: 10.1097/01.APO.0000580136.80338.d0. PubMed 31490199 ↗
  • Nair S, Kaur M, Sharma N, Titiyal JS. Refractive surgery and dry eye - An update. Indian J Ophthalmol. 2023 Apr;71(4):1105-1114. doi: 10.4103/IJO.IJO_3406_22. PubMed 37026241 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Oct 2025, 6 months.

Of 169 non-industry observational studies under Cataract, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 30. This study's 6 months is below that.

Counting every sponsor, half of 236 studies reached it within 16 months; a quarter within 9 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Nov 2025 → Oct 2025 and completion Nov 2025 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 20, 2024
StartActual
Mar 14, 2025
Primary completionActual
Oct 13, 2025was Nov 2025
CompletionActual
Mar 29, 2026was Nov 2025
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 6, 2026
Primary completion
Nov 2025→Oct 13, 2025 (actual)
Oct 6, 2026
Study completion
Nov 2025→Mar 29, 2026 (actual)
Oct 6, 2026
Enrollment
1000 (estimated)→60 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Completed
    Primary completion Nov 2025→Oct 13, 2025 (now actual)
    Study completion Nov 2025→Mar 29, 2026 (now actual)
    Enrollment 1000 (estimated)→60 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06743594
Collaborators
Taipei Nobel Eye Clinic
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Mar 14, 2025
Primary completion
Oct 13, 2025
Completion
Mar 29, 2026
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion